Espinoza Octavio
Chief Financial Officer
Espinoza Octavio has filed 11 SEC Form 4 filings (40 transaction rows) across 1 company, with disclosures dating back to 2025. 11 of those filings fall inside the rolling window. Most recent filing: Aug 14, 2026.
On the most recent filing, Espinoza Octavio is listed as Chief Financial Officer at LIGAND PHARMACEUTICALS INC. Inside the rolling window, Espinoza Octavio reported no open-market purchases and 4 open-market sales totaling $13.0M in LGND. The largest disclosed transaction in the window is a sale of 31,641 LGND shares on Aug 12, 2026, worth $9.2M.
Companies traded
Other insiders at LGND
Insider Buying
$0
reported purchases (SEC code P)
Insider Selling
$13.0M
reported sales (SEC code S)
Companies
1
in the rolling window
Frequently asked questions
How many SEC Form 4 filings has Espinoza Octavio made?
Espinoza Octavio has filed 11 SEC Form 4 filings (40 transaction rows) across 1 company since 2025.
Which companies does Espinoza Octavio trade?
Espinoza Octavio has filed SEC Form 4 disclosures for 1 company, including LGND.
When was Espinoza Octavio's most recent SEC Form 4 filing?
Espinoza Octavio's most recent SEC Form 4 filing on Tracefour is dated Aug 14, 2026.
What is Espinoza Octavio's job title?
On the most recent SEC Form 4 filings tracked by Tracefour, Espinoza Octavio is listed as Chief Financial Officer.
What is Espinoza Octavio's total buy and sell value in the current window?
Inside the rolling retention window, Espinoza Octavio bought $0 and sold $13.0M based on SEC Form 4 filings.
What was Espinoza Octavio's largest disclosed transaction?
The largest disclosed transaction in the current window is a sale of 31,641 LGND shares on 2026-08-12, worth $9.2M, per SEC Form 4 filings.